New York, Feb 27, 2026, 09:28 ET — Premarket
- GRAIL dropped roughly 5.9% in premarket trading, pulling back after a 12.2% surge on Thursday.
- Since last week’s U.K. NHS study update failed to hit its primary target, the stock’s been on a wild ride.
- Investors want more specifics from management when they take the stage at the TD Cowen conference next week.
GRAIL, Inc slid 5.9% to $54.70 in premarket action Friday, erasing some of Thursday’s 12.2% bounce that pushed shares to $58.10. Investors remain anxious about the Galleri blood test, the company’s key product.
Sentiment around GRAIL has swung sharply following the company’s disclosure that an early readout from a major U.K. study missed its main goal, reigniting doubts about the test’s prospects with regulators and insurers.
Traders are eyeing the next catalyst: a management presentation at TD Cowen’s health-care conference in Boston on March 3, after a stretch of unusually sharp moves.
The NHS-backed trial set out to see if adding Galleri to usual screening would reduce late-stage cancer cases. According to an update from the NHS-Galleri program, that main target wasn’t reached “in a statistically definite way.” Still, the update noted fewer stage IV cancers in the group that got the test. NHS-Galleri Trial
GRAIL is highlighting additional positive metrics, noting improvements like increased detection rates and more cancers caught at earlier stages. “We are excited to see the substantial reduction in Stage IV cancer diagnoses,” CEO Bob Ragusa said in a company release. GRAIL
A recent SEC filing containing the trial materials noted that further analyses are in progress, with full results on track for submission to the ASCO 2026 annual meeting. The document also named 12 cancer types singled out as the trial’s initial focus, with lung, colorectal, pancreatic, and ovarian cancers among them.
The company hasn’t shifted out of investment mode. Its latest quarterly results showed fourth-quarter revenue at $43.6 million, with the full year coming in at $147.2 million. Cash, cash equivalents and short-term marketable securities ended the year at $904.4 million.
The chart tells the story: a 50.6% plunge for the stock on Feb. 20, then a rebound—up 17.0% on Feb. 24, followed by gains of 2.9% and 12.2% on Feb. 25 and Feb. 26. Heading into Friday’s premarket, shares slipped again.
The path forward isn’t straightforward. Suppose future data points to a real move toward catching cases earlier; investors are then left figuring out if that actually leads to results regulators, insurers, and major screening initiatives will sign off on — and how long they’ll be waiting for that answer.
On Friday, the focus is whether early premarket softness sticks after the 9:30 a.m. ET bell. Eyes then shift to March 3, when management is expected to provide updates on trial follow-up, the FDA process, and the future steps for Galleri.
